Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

M-A: Convalescent plasma does not reduce mortality in COVID-19.

21 Nov, 2021 | 23:09h | UTC

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials – BMC Infectious Diseases

Related:

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – “The IFR was low for people younger than 51 years without comorbidity during the two waves (combined IFR = 3.36 per 100,000 infections)”.

21 Nov, 2021 | 23:12h | UTC

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – The Journal of Infectious Diseases

 

Commentary on Twitter

 

Is Delta the last Covid ‘super variant’?

21 Nov, 2021 | 23:07h | UTC

Is Delta the last Covid ‘super variant’? – The Guardian

 

No, vaccinated people are not ‘just as infectious’ as unvaccinated people if they get COVID.

21 Nov, 2021 | 23:05h | UTC

No, vaccinated people are not ‘just as infectious’ as unvaccinated people if they get COVID – The Conversation

 

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

21 Nov, 2021 | 22:56h | UTC

Single-dose HPV vaccine highly effective, researchers say – University of Washington School of Medicine

Related:

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here.

19 Nov, 2021 | 10:59h | UTC

Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here – BMC Public Health

 

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

19 Nov, 2021 | 11:01h | UTC

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited Commentary: Studying the coagulopathy of COVID-19 – The Lancet

 

Commentary from the author on Twitter (thread – click for more)

 

Global tuberculosis progress reversed by COVID-19 pandemic.

19 Nov, 2021 | 10:51h | UTC

Global tuberculosis progress reversed by COVID-19 pandemic – The Lancet Respiratory Diseases

Related:

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

How COVID is derailing the fight against HIV, TB and malaria.

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Tuberculosis and Covid-19: Fighting a deadly syndemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

 

Commentary on Twitter

 

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

19 Nov, 2021 | 10:57h | UTC

COVID-19 vaccines for children – Science

Related: Review: Should children under 12 years of age be vaccinated against COVID-19?

 

Commentary on Twitter

 

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

19 Nov, 2021 | 10:47h | UTC

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine – Nature Communications

Commentary: Long-term effectiveness of Pfizer/BioNTech two-dose regimen mRNA vaccine – News Medical

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 

Commentary on Twitter

 

Opinion: With 128 Covid vaccines in clinical development, we don’t know if the approved/authorized ones are the best ones.

19 Nov, 2021 | 10:45h | UTC

With 128 Covid vaccines in clinical development, we don’t know if the approved/authorized ones are the best ones – STAT

 

Review: Counting the neurological cost of COVID-19.

19 Nov, 2021 | 10:52h | UTC

Counting the neurological cost of COVID-19 – Nature Reviews Neurology

 

Commentary on Twitter

 

Perspective | The Future of SARS-CoV-2 Vaccination — Lessons from Influenza.

19 Nov, 2021 | 10:49h | UTC

The Future of SARS-CoV-2 Vaccination — Lessons from Influenza – New England Journal of Medicine

 

M-A: Intravenous iron is associated with increased risk of infection when compared with oral iron or no iron, which must be balanced with the potential benefits of reducing blood transfusion requirements.

19 Nov, 2021 | 10:31h | UTC

Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis – JAMA Network Open

Invited Commentary: Intravenous Iron and Infection Risk—Still an Unanswered Question – JAMA Network Open

 

Commentary on Twitter

 

M-A: Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality.

18 Nov, 2021 | 08:59h | UTC

Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis – The BMJ

 

Commentary on Twitter

 

Review: Should children under 12 years of age be vaccinated against COVID-19?

18 Nov, 2021 | 08:56h | UTC

Should children be vaccinated against COVID-19? – Archives of Disease in Childhood

 

Commentary from the author on Twitter (thread – click for more)

 

Covid: Children in UK told to delay jab for 12 weeks after infection.

18 Nov, 2021 | 08:54h | UTC

Covid: Children told to delay jab for 12 weeks after infection – BBC

Original Report: Joint Committee on Vaccination and Immunisation (JCVI) advice on COVID-19 vaccination in people aged 16 to 17 years: 15 November 2021

 

Observational study finds mRNA vaccination is associated with an effectiveness of 85% against Covid-19 hospitalization.

18 Nov, 2021 | 08:49h | UTC

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity – JAMA

Editorial: Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination – JAMA

Commentary: COVID-19 vaccines 85% effective against hospital cases but weaken over time – TCTMD

Related Study: Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

 

Observational study finds the effectiveness of mRNA vaccination against Covid-19 hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%).

18 Nov, 2021 | 08:52h | UTC

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Related:

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

 

Commentary on Twitter (thread – click for more)

 

8 lingering questions about the new Covid pills from Merck and Pfizer.

18 Nov, 2021 | 08:46h | UTC

8 lingering questions about the new Covid pills from Merck and Pfizer – STAT

Related:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Case-control study: sleep disorders linked to more severe outcomes from COVID-19, study suggests.

17 Nov, 2021 | 08:50h | UTC

News Release: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic

Original Study: Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System – JAMA Network Open

Commentary: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP

 

Commentary on Twitter

 

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic.

17 Nov, 2021 | 08:56h | UTC

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic – European Heart Journal

Part 1—epidemiology, pathophysiology, and diagnosis

Part 2—care pathways, treatment, and follow-up

News release: European Society of Cardiology COVID-19 guidance launched – European Society of Cardiology

 

Commentaries on Twitter

 

Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes.

17 Nov, 2021 | 08:53h | UTC

Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home – Annals of Internal Medicine

News Release: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine

Commentaries:

Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist

Texting saved lives during Covid. What does that mean for health care’s future? – STAT

 

Commentary from the author on Twitter (thread – click for more)

 

The big questions about Covid-19 booster shots – “From the why to the who, we still need a lot of answers about booster shots”.

17 Nov, 2021 | 08:48h | UTC

The big questions about Covid-19 booster shots – Vox

 

Commentary on Twitter

 

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries.

17 Nov, 2021 | 08:40h | UTC

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay

See also:

Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR

Pfizer and Medicines Patent Pool Reach ‘Ground-breaking’ Voluntary Licensing Deal for New COVID-19 Treatment Pill – Health Policy Watch

Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (a few articles per month are free)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.